- Jade Biosciences announced a **private financing of approximately $135 million in gross proceeds**, which is expected to **fund operations into 2028**.  **[1798749_2170576_1]** **[1798749_2170576_2]** **[1798749_2170576_7]** 
- The financing will support the clinical development of **JADE one zero one**, currently in Phase 1, with interim biomarker data anticipated in **2026**, and its progression into late-stage IgAN patient trials.  **[1798749_2170576_2]** **[1798749_2170576_7]** 
- Funds will also advance **JADE two zero one**, a half-life extended monoclonal antibody targeting BAFR with a **total addressable market of over $80 billion**, into its first-in-human study in **rheumatoid arthritis patients in 2026**.  **[1798749_2170576_2]** **[1798749_2170576_3]** **[1798749_2170576_6]** **[1798749_2170576_7]**

Jade Biosciences Secures $135 Million Private Financing and Outlines Pipeline Advancement

- Jade Biosciences has secured **$135 million** in additional financing, which is expected to support its cash runway into **H1 2028**.  **[1798749_2170404:6]** **[1798749_2170404:10]** 
- The company is advancing its pipeline of therapies for autoimmune diseases, including **JADE101**, **JADE201**, and **JADE-003**.  **[1798749_2170404:6]** **[1798749_2170404:10]** 
- The **JADE201** program, an anti-BAFF-R antibody, is slated to begin its First-in-Human trial in **H1 2026** for rheumatoid arthritis patients.  **[1798749_2170404:6]** **[1798749_2170404:9]** 
- Preclinical data for **JADE201** indicate a differentiated profile with **>2X half-life extension** in NHPs compared to ianalumab, suggesting potential for best-in-class efficacy and infrequent dosing across a broad range of autoimmune indications with an addressable market of over **$80 billion**.  **[1798749_2170404:9]** **[1798749_2170404:10]**

Jade Biosciences Provides Pipeline Update and Extends Cash Runway

- **Jade Biosciences** announced a **$135 million private placement (PIPE) financing**.  **[1798749_0001193125-25-232562_d58004dex991.htm:0]** 
- The financing included the sale of **13,368,164 shares of common stock at $9.14 per share** and **1,402,092 pre-funded warrants at $9.1399 per pre-funded warrant**.  **[1798749_0001193125-25-232562_d58004dex991.htm:0]** 
- The company expects the net proceeds, combined with existing cash, to fund operations into the **first half of 2028**.  **[1798749_0001193125-25-232562_d58004dex991.htm:0]** 
- Following the transaction, there will be approximately **67.4 million shares** of Common Stock and Common Stock equivalents issued and outstanding on a pro forma basis.  **[1798749_0001193125-25-232562_d58004dex991.htm:0]** **[1798749_0001193125-25-232562_d58004d8k.htm:3]** 
- Key investors participating in the PIPE include Janus Henderson Investors, Fairmount, RA Capital Management, Marshall Wace, Aberdeen Investments, Great Point Partners, LLC, Venrock Healthcare Capital Partners, Samsara BioCapital, and Avidity Partners.  **[1798749_0001193125-25-232562_d58004dex991.htm:0]**

Jade Biosciences Announces $135 Million Private Placement

- Jade Biosciences' lead program, **Jade 101**, an anti-APRIL antibody for IGAN, has entered the clinic with the first cohort dosed earlier this month.  **[1798749_2145756_0]**  The company anticipates a **first-in-human readout in the first half of next year (2026)**, which will characterize Jade 101 through a healthy volunteer study.  **[1798749_2145756_0]** 
- Jade 101 is designed for **best-in-class clinical activity** and convenient dosing, targeting one subcutaneous injection no more frequently than **every eight weeks**.  **[1798749_2145756_0]**  It features **ultra-high binding affinity** (approximately **50 femtomolar KD** to APRIL, which is **750-fold higher than sibeprenlimab** and **2,000-fold higher than zygelimab**) and half-life extension.  **[1798749_2145756_2]** **[1798749_2145756_9]** 
- The company reported **$221 million** in cash at the end of the last quarter, providing a financial runway to advance its three programs through **2027**.  **[1798749_2145756_6]** 
- Beyond IGAN, Jade Biosciences plans to explore other potential indications for its anti-APRIL mechanism, including **IgM-driven diseases** such as multifocal motor neuropathy, anti-MAG neuropathy, and cold agglutinin disease.  **[1798749_2145756_5]** **[1798749_2145756_12]**

Jade Biosciences Discusses Clinical Progress and Financial Outlook

- Jade Biosciences, led by former Chinook Therapeutics executives, is focused on developing best-in-class therapeutics for autoimmune indications, with a lead anti-April asset, JAD-101, targeting IgA Nephropathy (IgAN).  **[1798749_tx_379077_0]** 
- The company recently became clinical-stage, having dosed the first cohort of healthy volunteers for JAD-101, with an interim readout from the year-long Phase 1 study anticipated in **2026**.  **[1798749_tx_379077_0]** **[1798749_tx_379077_4]** 
- JAD-101 aims to be a best-in-class anti-April therapeutic for the **$10 billion+** IgAN market, targeting a single subcutaneous injection no more frequently than **every eight weeks**.  **[1798749_tx_379077_2]** **[1798749_tx_379077_3]** 
- Jade Biosciences is well-financed, having raised **$300 million** through a convertible note financing during a reverse merger in April, providing funding through **2027**.  **[1798749_tx_379077_0]** 
- The company plans to advance its second asset, a B cell depleting agent, into the clinic in the **first half of 2026**, with a third asset following in **2027**.  **[1798749_tx_379077_0]** **[1798749_tx_379077_7]** **[1798749_tx_379077_8]**

Jade Biosciences (JBIO)